CARVYKTI® (ciltacabtagene autoleucel) is a treatment used for adult patients who have cancer of the bone marrow called multiple myeloma. It is used when at least one other treatment has not worked or has stopped working. CARVYKTI® is a medicine made from your own white blood cells, which have been changed (genetically modified) to recognize and attack your multiple myeloma cells.

  • SIGN UP FOR UPDATES
  • US Healthcare Professionals
Logo
  • Home
    ABOUT
    CARVYKTI®
    What is CARVYKTI®?
    How CARVYKTI® Works
    Clinical Efficacy
    Safety Profile
    RECEIVING CARVYKTI®
    Treatment
    Patient Eligibility
    CARVYKTI® Treatment Process
    Planning for CARVYKTI® Treatment
    RESOURCES
    AND SUPPORT
    MyCARVYKTI® Patient Support Program
    Patient Resources
    Care Partner Resources
    PATIENT AND
    CARE PARTNER STORIES
    FIND A CERTIFIED
    TREATMENT CENTER
    Sign up for updates
  • IMPORTANT SAFETY INFORMATION
    PRESCRIBING INFORMATION
    Prescribing Information—English PDFPrescribing Information—Spanish PDF
    MEDICATION GUIDE
    REMS PROGRAM
    Resources in more Languages
    For Us Patients & Care Partners
    VISIT US HEALTHCARE PROFESSIONAL SITE

Site Map

  • Home
  • About CARVYKTI®
    • What is CARVYKTI®?
    • How CARVYKTI® Works
    • Clinical Efficacy
    • Safety Profile
  • Receiving CARVYKTI® Treatment
    • Patient Eligibility
    • CARVYKTI® Treatment Process
    • Planning for CARVYKTI® Treatment
  • Resources and Support
    • MyCARVYKTI® Patient Support Program
    • Patient Resources
    • Care Partner Resources
  • Patient and Care Partner Stories
  • Find a Certified Treatment Center
  • Sign up for Updates
  • Important Safety Information
  • Prescribing Information
    • Prescribing Information—English PDF
    • Prescribing Information—Spanish PDF
  • Medication Guide
  • REMS Program
  • Resources in More Languages
  • For US Patients & Care Partners
  • Visit US Healthcare Professional Site
  • Contact Us
  • Cookie Policy
  • Privacy Policy
  • Legal Notice